Axial Therapeutics
Axial Biotherapeutics develops gut-restricted small molecules for treating central nervous system disorders.
Founded
2016Axial Biotherapeutics develops gut-restricted small molecules for treating central nervous system disorders.
Axial Therapeutics, founded with a mission to revolutionize medicine through microbiome science, focuses on developing gut-restricted small molecules to treat central nervous system disorders. The company aims to harness the untapped potential of the gut microbiome to create innovative therapeutics for conditions such as autism spectrum disorder, Parkinson’s disease, liver disease, and oncology. Their market focus is primarily on patients in the United States who suffer from these debilitating diseases.
Notable affiliated individuals include leading scientists and researchers in microbiome science and central nervous system disorders. Axial Therapeutics has garnered attention from prominent investors in the biopharmaceutical sector. Key achievements include advancing their lead product candidates into clinical studies, demonstrating significant potential in treating complex diseases. The overall impact of Axial Therapeutics lies in its pioneering approach, which could lead to groundbreaking treatments and improved patient outcomes in several challenging medical fields.
Companies similar to Axial Therapeutics include Axsome Therapeutics, Axonis Therapeutics, Axerion Therapeutics and Autobahn Therapeutics.
Axial Therapeutics was founded in 2016.
Axial Therapeutics' headquarters is located in Woburn, MA, US.
Axial Therapeutics' most recent funding round was for $37.3M (USD) in October 2021.
As of Oct 13, 2021, Axial Therapeutics has raised a total of $110.9M (USD).
Axial Therapeutics has 29 employees as of Feb 5, 2024.
Axerion Therapeutics
